Tasuku Honjo was born in Kyoto, Japan on January 27, 1942. He graduated from Kyoto University and is an immunologist. Winner of the 2018 Nobel Prize in Physiology or Medicine, foreign academician of the National Academy of Sciences, and member of the Japanese Academy of Sciences. He is now the Special Professor of the Institute of Higher Studies of Kyoto University, the Legal Director of Shizuoka Public University, and a cultural contributor.

In 1992, we discovered the T-cell inhibitory receptor PD-12, and in 2013, we pioneered cancer immunotherapy based on this. Our achievements ranked first in the annual top ten scientific breakthroughs of Science. At the same time, we are famous for the molecular identification of cytokines IL-4 and IL-5, and the discovery of activation induced cytidine deaminase (AID) that plays an important role in class transformation, recombination and somatic hypermutation.

Benshu is the winner of the "Koho Prize" of the Robert Koho Prize, the highest prize in German medicine, and is known as "one of the Japanese closest to the Nobel Prize". In 2014, he and James Allison jointly won the first Tang Prize for Biotechnology and Medicine [1]. On September 21, 2016, he was selected into the list of 2016 Citation Laureate Awards. On September 25, 2016, the second Tang Prize awarding ceremony was held grandly. Ben Shuyou, the winner of the first Tang Prize for Medical Sciences, won the prize [2]. In December 2016, it was awarded the first "Fudan Zhongzhi Science Award" [3]. On October 1, 2018, the 2018 Nobel Prize in Physiology or Medicine was announced, and James Allison and Ben Shuyou jointly won the prize, in recognition of their "contributions to the discovery of negative immunomodulation therapy for cancer".

本庶佑（Tasuku Honjo），1942年1月27日出生于日本京都府京都市，毕业于京都大学，免疫学家。2018年诺贝尔生理学或医学奖获得者，美国国家科学院外籍院士，日本学士院会员。现任京都大学高等研究院特别教授、静冈县公立大学法人理事长，文化功劳者。

本庶佑于1992年发现T细胞抑制受体PD-1，2013年依此开创了癌症免疫疗法，功绩名列《Science》年度十大科学突破之首。本庶同时因对细胞因子IL-4、IL5的分子鉴定，及发现对类转换重组及体细胞超变异具有重要作用的活化诱导胞苷脱氨酶(Activation-induced Cytidine Dearminase, AID)而知名。

本庶是德国医学最高奖罗伯·柯霍奖的“科霍奖”得主，被誉为“最接近诺贝尔奖的日本人之一”。2014年与詹姆斯·艾利森共同获得首届唐奖生技医药奖 [1]  。2016年9月21日，入选2016年引文桂冠奖名单。2016年9月25日，第二届唐奖颁奖典礼盛大举行，首届唐奖生医奖得主本庶佑获奖 [2]  。2016年12月，获颁首届“复旦-中植科学奖” [3]  。2018年10月1日，2018年诺贝尔生理学或医学奖揭晓，詹姆斯·艾利森和本庶佑共同获奖，以表彰他们“发现负性免疫调节治疗癌症的疗法方面的贡献”。

https://baike.baidu.com/item/%E6%9C%AC%E5%BA%B6%E4%BD%91/15826826?fromModule=lemma_inlink

https://pubmed.ncbi.nlm.nih.gov/19234458/

https://pubmed.ncbi.nlm.nih.gov/?term=Honjo+T&cauthor_id=19234458

summary-HonjoT-set.txt

http://www.pubmedplus.cn/P/SearchQuickResult?wd=75d770b7-c510-4257-a2b4-92b834e8319e

• 年份

• 记录数占%

• 期刊

• 记录数占%

• 国家

• 记录数占%

• 中国城市

• 境外城市

• 记录数占%

• 主题词

• 记录数占%